You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 4,962,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,962,098
Title: Graduated estrogen contraceptive
Abstract:Contraceptive methods and delivery systems involving few undesirable side effects during administration are based on novel triphasic estrogen/progestogen combinations, wherein the amount of estrogen is increased stepwise over the three phases.
Inventor(s): Boissonneault; Roger M. (Long Valley, NJ)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:07/340,974
Patent Claims: 1. A method of contraception comprising the steps of sequentially-administering to a female of child bearing age:

(1) for about 4 to about 7 days, a composition I containing about 0.5-1.5 mg norethindrone acetate and about 10-50 mcg ethinyl estradiol,

(2) for about 5 to about 8 days, a composition II containing about 0.5-1.5 mg norethindrone acetate and about 10-50 mcg ethinyl estradiol, and

(3) for about 7 to about 12 days, a composition III containing 0.5-1.5 mg norethindrone acetate and about 10-50 mcg ethinyl estradiol, wherein the amount of ethinyl estradiol is increased stepwise by the amount of at least 5 mcg in each step.

2. The method of claim 1 which comprises the additional step of administering, for about 7 days, a composition IV containing ferrous fumarate.

3. The method of claim 1 wherein composition I contains about 0.5-1.5 mg norethindrone acetate and about 10-30 mcg ethinyl estradiol; composition II contains 0.5-1.5 mg norethindrone acetate and 20-40 mcg ethinyl estradiol; and composition III contains 0.5-1.5 mg norethindrone acetate and about 30-50 mcg ethinyl estradiol.

4. The method of claim 1 wherein composition I is administered for about 5 days and contains about 1.0 mg norethindrone acetate and about 20 mcg ethinyl estradiol; composition II is administered for about 7 days and contains about 1.0 mg norethindrone acetate and about 30 mcg ethinyl estradiol; and composition III is administered for about 9 days and contains about 1.0 mg norethindrone acetate and about 40 mcg ethinyl estradiol.

5. The method of claim 4 wherein the compositions are administered in combination with a suitable carrier.

6. The method of claim 1 wherein composition I is administered for about 5 days and contains about 1.0 mg norethindrone acetate and about 20 mcg ethinyl estradiol; composition II is administered for about 7 days and contains about 1.5 mg norethindrone acetate and about 30 mcg ethinyl estradiol; and composition III is adminstered for about 9 days and contains about 1.0 mg norethindrone acetate and about 50 mcg ethinyl estradiol.

7. The method of claim 6 wherein the compositions are administered in combination with a suitable carrier.

8. The method of claim 1 wherein composition I is administered for about 5 days and contains about 1.0 mg norethindrone acetate and about 20 mcg ethinyl estradiol; composition II is administered for about 7 days and contains about 1.0 mg norethindrone acetate and about 30 mcg ethinyl estradiol; and composition III is administered for about 9 days and contains about 1.0 mg norethindrone acetate and about 35 mcg ethinyl estradiol.

9. The method of claim 8 wherein the compositions are administered in combination with a suitable carrier.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.